Affiliation:
1. National Institute for Infectious Diseases “Lazzaro Spallanzani”—IRCCS, 00149 Rome, Italy
2. Department of Medicine, UniCamillus International University, 00131 Rome, Italy
Abstract
Over the past years, Tuberculosis (TB) control strategies have been effective in reducing drug-resistant (DR) TB globally; however, a wider implementation of new diagnostic strategies, such as Whole genome sequencing (WGS), would be critical for further improvement. The aim of this study, based on WGS of Mycobacterium tuberculosis (MTB) strains isolated in a TB referral center over 6 years, was to evaluate the efficacy of this methodology in improving therapy guidance for clinicians and in improving the understanding of the epidemiology of TB transmission. WGS was performed in addition to pDST on 1001 strains consecutively isolated between January 2016 and December 2021; the results allowed us to improve the quality of data on resistance and to identify possible clusters of transmission. Prediction of rifampicin-resistant (RR) or multi-drug-resistant TB strains (MDR-TB, defined as resistance to at least rifampicin and isoniazid) was obtained for 50 strains (5%). Mutations predictive of an MDR isolate were further characterized, and Ser450Leu and Ser315Thr were found to be the most frequent mutations in rpoB and katG genes, respectively. Discordances between WGS and phenotypic drug susceptibility testing (pDST) were found in few strains, and their impact on clinical decisions and outcome was addressed. The introduction of WGS in our Institute improved our diagnostic routine, allowing accurate patient management, and was a valid instrument for epidemiological investigations and infection control.
Funder
Italian Ministry of health
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference30 articles.
1. World Health Organization (2024, January 15). Global Tuberculosis Report 2023. Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023.
2. (2024, January 15). Tuberculosis Surveillance and Monitoring in Europe-2023–2021 Data. Available online: https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2023-2021-data.
3. (2024, January 15). Tuberculosis—Annual Epidemiological Report for 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/tuberculosis-annual-epidemiological-report-2021.
4. (2024, January 15). REPORT SERESMI 2019–2020. Available online: https://www.inmi.it/wp-content/uploads/2022/05/Tubercolosi-Regione-Lazio.-Aggiornamento-2020.pdf.
5. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: A 2023 TBnet/RESIST-TB consensus statement;Boeree;Lancet Infect Dis.,2023